ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 780

Changes in MiR-17-92 Cluster Expression Link Systemic Juvenile Idiopathic Arthritis, Monocyte-to-Macrophage Differentiation, and Interferon Regulation

Divya Takellapti1, Xiaoling Niu 2, Thuy Do 3 and Grant Schulert 3, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Fudan University, Shanghai, Shanghai, China (People's Republic), 3Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: macrophage activation syndrome, Macrophage and MicroRNA, monocytes, Systemic JIA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: MicroRNAs (miRNAs) are small noncoding RNAs which post-transcriptionally regulate gene expression. The miR-17-92 cluster is well characterized; its overexpression has been found to serve a major oncogenic role in the targeting and downregulation of tumor-suppressive pathways. Our previous work identified several members of the cluster with significantly higher levels in monocytes from patients with active Systemic Juvenile Idiopathic Arthritis (SJIA), a chronic inflammatory disease of childhood. Children with SJIA are at risk for life-threatening complications including Macrophage Activation Syndrome (MAS), an episode of overwhelming inflammation driven by IFNɤ. The objectives of this study were to characterize the regulation of the miR-17-92 cluster, define key targets, and determine the cluster’s role in inflammation and SJIA.

Methods: MiRNA levels were examined in THP-1 cells and primary human monocytes over the course of the monocyte to monocyte-derived macrophage (MDM) transition. MiR-17, miR-19a, and miR-20a were overexpressed in CD14+ monocytes for 2 days. Transcriptional profiles were performed using Ampliseq Transcriptome and the Ion Torrent S5 system and analyzed using AltAnalyze. Potential targets of the miR-17-92 cluster were then validated via dual-luciferase reporter assay.

Results: Neither blood monocytes nor fully differentiated THP-1 cells showed significant changes in miR-17-92 levels under standard polarization conditions, including M1, M2a, and M2b conditions, or IL-6 and IL-10 stimulation. The most sizable changes in miR-17-92 levels were found during monocyte to macrophage transition. Interestingly, primary monocytes showed increases in miR-17-92 levels within the first 48 hours of differentiation towards MDM similar to that seen in SJIA monocytes. In contrast, both PMA-differentiated THP1 cells and fully differentiated MDMs showed decreased miR-17-92 compared to undifferentiated monocytic cells. MiR-17-92 was overexpressed in primary monocytes to model these early transition changes. Genome-wide transcriptional profiling showed an upregulation of genes involved in Type I and II Interferon pathways, including response to interferon-alpha (adjusted p=2.71×10-12) and interferon-gamma (adjusted p=7.81×10-9). Analysis of genes significantly downregulated by miR-17, miR-19a, or miR-20a identified several putative and previously validated miR-17-92 cluster targets, including ATG5, IFRD2, JAK1, PPARG, and PTPN2 which have interferon-regulatory functions. Dual-luciferase reporter assay experiments support that these genes are direct targets of miR-17, miR-19a, and/or miR-20a.

Conclusion: MiR-17-92 demonstrates initial increase followed by subsequent decrease in human monocyte to macrophage differentiation. Overexpression of miR-17-92 upregulates Type I and II interferon pathway genes, and these miRNAs target multiple genes involved in regulating interferon signaling and/or inflammatory response. Taken together, miR-17-92 overexpression in SJIA monocytes may suggest a more differentiated phenotype, and contribute to IFNɤ sensitivity and risk for MAS.


Disclosure: D. Takellapti, None; X. Niu, None; T. Do, None; G. Schulert, Novartis, 5, 8.

To cite this abstract in AMA style:

Takellapti D, Niu X, Do T, Schulert G. Changes in MiR-17-92 Cluster Expression Link Systemic Juvenile Idiopathic Arthritis, Monocyte-to-Macrophage Differentiation, and Interferon Regulation [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/changes-in-mir-17-92-cluster-expression-link-systemic-juvenile-idiopathic-arthritis-monocyte-to-macrophage-differentiation-and-interferon-regulation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/changes-in-mir-17-92-cluster-expression-link-systemic-juvenile-idiopathic-arthritis-monocyte-to-macrophage-differentiation-and-interferon-regulation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology